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The susceptibility to b-lactams and the b-lactamase content of 110 Salmonella spp. blood
isolates collected during 1997–98 in 19 European centers participating in the SENTRY
Surveillance Program were studied. Thirty-one isolates (28%) were resistant to penicil-
lins, due to production of TEM-1 (27 isolates), OXA-1 (three isolates) or TEM-1þOXA-1
(one isolate). All OXA-1 producers and 10 TEM-1-producing isolates were also resistant
to penicillin–clavulanic acid combinations. In the latter isolates, this phenotype was
associated with increased production of TEM-1. Sixteen TEM-1-producing Salmonella
Enteritidis isolates and one OXA-1-producing S. Typhimurium isolate were able to transfer
b-lactam resistance by conjugation.
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b-Lactam antibiotics, along with fluorinated qui-
nolones, are the antibiotics of choice in the treat-
ment of extraintestinal salmonella infections. A
high proportion of Salmonella clinical strains pro-
duce common penicillinases such as TEM- and
PSE-type enzymes [1,2]. There have also been
recent studies reporting on the emergence of Sal-
monella strains producing various b-lactamases
with a broad spectrum of activity that usually
includes oxyimino-cephalosporins [3,4].
The aim of the SENTRY Antimicrobial Surveil-
lance Program is to monitor isolation frequencies
and antibiotic resistance trends of pathogenic
microorganisms. This ongoing project operates
through a worldwide network of sentinel hospi-
tals. Analysis of data from European centers dur-
ing 1998 showed that Salmonella ranks eleventh
among the genera most frequently isolated from
bloodstream infections [5]. In this study, we pre-
sent the status of susceptibility to b-lactams and
the respective resistance mechanisms of these Sal-
monella spp. isolates.
In total, 110 Salmonella spp. isolates derived
from blood cultures during 1997–98 in 19 Eur-
opean centers were included in the study.
Thirty-four were serotyped as S. Enteritidis and
21 as S. Typhimurium. Forty isolates were not
characterized at the serotype level. The remaining
isolates were distributed among various other
serotypes. The isolates were collected for the SEN-
TRY Program and deposited at the Eijkman-Wink-
ler Institute for Microbiology, University Medical
Center, Utrecht, The Netherlands. More details on
the operation of this global surveillance system are
given elsewhere [5,6]. Species identification was
confirmed by the API 20E system (bioMerieux,
Marcy l’Etoile, France). For selected isolates, ser-
otyping results were confirmed at the National
Reference Center for Salmonella and Shigella,
School of Public Health, Athens, Greece (M. Lam-
biri and N. Vakalis, personal communication).
Susceptibility testing for b-lactams and other
antimicrobials was performed by a broth micro-
dilution method as recommended by the National
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(NCCLS) [7]. Screening for production of
extended-spectrum b-lactamases (ESBLs) was per-
formed by the conventional double disk synergy
test using an amoxicillin–clavulanate disk sur-
rounded by cefotaxime, ceftazidime, aztreonam
and cefepime disks at a distance of 30 mm (center
to center). Occasionally, ESBL-detecting E test
strips (AB Biodisk, Solna, Sweden) were used
for confirmation.
Conjugal transfer of resistance to b-lactam anti-
biotics was performed in mixed broth cultures as
described previously [4]. An Escherichia coli K12
strain highly resistant to rifampicin was used as
recipient. Transconjugant clones were selected on
nutrient agar containing ampicillin (50 mg/L) and
rifampicin (200 mg/L). The frequency of transfer
(transconjugants obtained per donor cell) was also
estimated.
b-Lactamase preparations were obtained by
ultrasonic treatment of bacterial cell suspensions.
Extracts were clarified by centrifugation, and the
protein content was determined with a protein
assay kit (Bio-Rad, Munchen, Germany). Quanti-
fication of b-lactamase activity was done by spec-
trophotometry using the chromogen nitrocefin
(Unipath, Basingstoke, UK) as substrate. Isoelec-
tric points (pIs) of b-lactamases were determined
by isoelectric focusing (IEF) in polyacrylamide gels
containing ampholytes covering a pH range from
3.5 to 9.5 (Pharmacia-Biotech, Piscateway, NJ,
USA). b-lactamases with known pIs (TEM-1,
PSE-2, SHV-1 and SHV-5) were used as controls.
b-Lactamase bands were visualized in situ with a
nitrocefin solution.
PCR assays for the detection of bla genes were
performed using oligonucleotide primers specific
for the respective genes. For blaTEM and blaPSE,
primers and PCR conditions as described by
Llanes et al. were used [1]. For amplification
of a segment of blaOXA-1, primers 5
0-GCAT-
CCACAAACGCTGAAATTG-30 (forward) and
50-GAGCCATGCTTCTGTTAATCCG-30 (reverse),
encompassing nucleotides 1504–1852 of a pub-
lished sequence (GenBank accession number
J02967), were used.
Data are presented in Table 1. b-Lactam-resis-
tant isolates were obtained by 13 of the 19 parti-
cipating centers. In total, 31 of the 110 isolates
(28%) exhibited high-level resistance to ampicillin;
all were also resistant to ticarcillin. Fourteen were
S. Typhimurium and 13 S. Enteritidis. The remaining
four belonged to the serotypes Typhi, Dublin,
Glostrup and Bredeney. Fifteen isolates (10 S.
Typhimurium and five S. Enteritidis) were also
resistant to piperacillin. Of the 31 ampicillin-resis-
tant isolates, 13 (10 S. Typhimurium and three S.
Enteritidis) were also resistant to at least one of the
two penicillin–clavulanate combinations tested.
All MICs of piperacillin–tazobactam were below
the breakpoint for resistance (128/4 mg/L). Nev-
ertheless, two S. Typhimurium isolates exhibited
decreased susceptibility to this combination.
Resistance to cefazolin was observed in three iso-
lates. Cefotaxime, ceftriaxone, ceftazidime, aztreo-
nam and cefepime were highly active against all 31
isolates (data not shown). There was no indication
of production of ESBLs by the synergy tests
employed.
In the IEF experiments, 27 isolates were found to
produce a b-lactamase with a pI equal to 5.4. This
enzyme was most probably TEM-1, since all 27
isolates were also positive in the blaTEM-detecting
PCR assays. Resistance to penicillins could be
transferred from 17 of these isolates. Notably,
conjugal transfer of TEM-1 was achieved with 12
S. Enteritidis but only two S. Typhimurium isolates.
In addition, the frequency of transfer by S. Enter-
itidis was, on average, two orders of magnitude
higher than that observed with S. Typhimurium.
One S. Enteritidis and three S. Typhimurium isolates
produced a b-lactamase with a pI of 7.4 and were
also positive in the blaOXA-1 assays. A low-fre-
quency conjugal transfer of OXA-1 was achieved
with only one S. Typhimurium isolate (also produ-
cing TEM-1) which had been isolated in Albania.
The properties and relative quantities of b-lac-
tamases produced may explain, at least in part, the
differences in isolates’ b-lactam resistance pat-
terns. Comparison of specific activities against
nitrocefin indicated that the penicillin-inhibitor-
resistant isolates produced significantly higher
quantities of TEM-1 than the susceptible isolates.
Resistance to amoxicillin–clavulanate due to over-
production of TEM-1 in Salmonella has also been
reported in previous studies [8]. This mechanism
may also be associated with the high-level resis-
tance to cefazolin observed in three of the isolates
examined here. On the other hand, production of
inhibitor-resistant TEM enzymes that also exhibit a
pI of 5.4, such as TEM-39, -40 and -44, particularly
among the penicillin-inhibitor-resistant, cefazolin-
susceptible isolates, cannot be excluded. All four
OXA-1 producers were resistant to at least one of
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the penicillin-inhibitor combinations tested. It is
likely that this phenotype was determined by the
relatively low sensitivity of OXA-1 to b-lactamase
inhibitors as compared with TEM and other class
A enzymes. Susceptibility of OXA-1 producers to
cefazolin is in line with the weak activity of this b-
lactamase against most narrow-spectrum cepha-
losporins [9].
In conclusion, the present study indicates that a
considerable percentage of S. Typhimurium and S.
Enteritidis strains isolated during 1997–98 from
bloodstream infections in European hospitals were
resistant to b-lactams, mostly due to the produc-
tion of TEM-1. TEM-1 was also produced by an S.
Bredeney isolate and an S. Glostrup isolate. To our
knowledge, the presence of TEM in these sero-
types has not been described before. The frequent
occurrence of blaTEM among salmonellae has also
been observed in previous studies conducted in
European countries [1,10]. On the other hand,
OXA-type b-lactamases are encountered much less
frequently than TEM among Salmonella isolates.
Three of the four OXA-1-producing isolates in the
present study were from Spain. This is consistent
with a recent report on the isolation of S. Typhi-
murium with OXA-1 in this country [10]. Never-
theless, we cannot provide a plausible explanation
for the absence of strains producing PSE-1, a fre-
quent enzyme among multiresistant S. Typhimur-
ium [1,2,10]. Notwithstanding the sampling
limitations of sentinel surveys, it is expected that
the SENTRY Program will efficiently monitor the
rapid evolution of antimicrobial drug resistance
trends in Salmonella.
Table 1 Characteristics of 31 b-lactam-resistant Salmonella spp. clinical isolates
No Serotype
Date of
isolation
Place of
isolation
b-Lactam
resistancea pI
PCRþ
for
bla
transfer
1 Typhimurium 01/98 Paris A, T, P, Tc 5.4 tem 
2 Typhimurium 03/98 Paris A, T, P, Ac, Tc 5.4 tem 
3 Typhimurium 05/97 Lille A, T, P, Ac, (Tc) 5.4 tem þ
4 Typhimuriumb 11/97 Lille A, T, P, Ac 5.4 tem 
5 Typhimurium 07/98 Lyon A, T, P, (Tc), (Cf) 5.4 tem 
6 Typhimuriumb 11/97 Madrid A, T, (P), Ac 7.4 oxa-1 
7 Typhimuriumb 04/98 Madrid A, T, P, Ac, Tc 5.4 tem 
8 Typhimurium 05/98 Barcelona A, T, P, Ac, Tc, (Pz) 7.4 oxa-1 
9 Typhimurium 07/98 Barcelona A, T, P, Ac, Tc 5.4 tem 
10 Typhimurium 04/98 Freiburg A, T, P, Ac, Tc 5.4 tem 
11 Typhimurium 04/98 Lausanne A, T, (P) 5.4 tem þ
12 Typhimurium 05/98 Coimbra A, T, (P) 5.4 tem 
13 Typhimurium 10/98 Genova A, T, (P) 5.4 tem 
14 Typhimuriumb 10/97 Tirana A, T, P, Ac, Tc, (Pz), Cf 5.4þ 7.4 temþ oxa-1 þ (7.4)
15 Enteritidisb 09/98 Madrid A, T, P, (Tc) 5.4 tem þ
16 Enteritidis 07/97 Barcelona A, T, (P), Ac, Tc 7.4 oxa-1 
17 Enteritidis 09/97 Barcelona A, T, (P) 5.4 tem þ
18 Enteritidis 05/98 Barcelona A, T, P 5.4 tem þ
19 Enteritidis 06/98 Barcelona A, T, (P) 5.4 tem þ
20 Enteritidis 06/98 Barcelona A, T, P 5.4 tem þ
21 Enteritidis 06/98 Barcelona A, T, (P) 5.4 tem þ
22 Enteritidis 09/97 Sevilla A, T, (P) 5.4 tem þ
23 Enteritidis 12/97 Sevilla A, T, (P) 5.4 tem þ
24 Enteritidis 06/98 Sevilla A, T, P, Ac, Tc 5.4 tem þ
25 Enteritidis 12/98 Sevilla A, T, P, Ac, Tc, Cf 5.4 tem þ
26 Enteritidis 08/98 Athens A, T, (P) 5.4 tem þ
27 Enteritidisb 08/98 Athens A, T, (P) 5.4 tem þ
28 Typhi 07/97 Athens A, T, (P) 5.4 tem þ
29 Dublin 10/97 Sevilla A, T 5.4 tem þ
30 Glostrupb 04/97 Paris A, T, P, (Tc), Cf 5.4 tem 
31 Bredeneyb 06/97 Athens A, T, (P) 5.4 tem þ
aA, ampicillin; T, ticarcillin; P, piperacillin; Ac, amoxicillin–clavulanate; Tc, ticarcillin–clavulanate; Pz, piperacillin–
tazobactam; Cf, cefazolin. Parentheses indicate intermediate susceptibility according to NCCLS criteria.
bSerotyped at the National Reference Center for Salmonella and Shigella, Athens, Greece.
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